Caveolin-1 exhibits a stage-dependent, functional fluctuation during pancreatic cancer development, but the underlying mechanisms remain unclear. Here, we report that cavin-1, a structural protein of caveolae, modulates the oncogenic function of caveolin-1 and cooperates with caveolin-1 to enhance pancreatic cancer aggressiveness. Cavin-1 expression is associated with caveolin-1 in pancreatic cancer tissue samples and cell lines, and predicts the metastatic potential of pancreatic cancer. Interactome analyses further revealed the physical interaction of cavin-1 and caveolin-1 and their colocalization in pancreatic cancer cells. Cavin-1 stabilizes caveolin-1 expression or activity by inhibiting its internalization and subsequent lysosomal degradation. More in-depth functional experiments showed that caveolin-1-enhanced aggressiveness of pancreatic cancer cells is dependent on the presence of cavin-1. In contrast, cavin-1 depletion inhibited the invasion and metastasis of pancreatic cancer cells, which could not be restored by caveolin-1-rescue construct. Tissue microarray analyses in two independent clinic cohorts also supported the augment of cavin-1 on the prognostic potency of caveolin-1, and showed that combination of cavin-1 with caveolin-1 predicted worse survival in pancreatic cancer patients. Of note, the phenotypes because of cavin-1 could not be achieved by other cavins such as cavin-2, and the tumor-promoting role of cavin-1 in pancreatic cancer was found to be largely dependent on caveolin-1 expression, which highlights the critical role of cavin-1/caveoin-1 in pancreatic cancer progression, and suggests that the interruption of cavin-1/caveolin-1 interaction is a promising therapeutic strategy for pancreatic cancer.
INTRODUCTION
Caveolin-1 is an essential caveolae scaffold protein and acts as a tumor modulator involved in cellular transformation, tumor growth, cell metastasis, multi-drug resistance and angiogenesis. 1, 2 However, its precise role as a tumor suppressor or oncogene in human malignancies remains elusive. In ovarian, 3 colon, 4 breast cancers 5 and sarcomas, 6 caveolin-1 is downregulated and negatively correlated with the metastatic potential of tumor cells. Whereas it is increased in bladder, 7 esophageal 8 and prostate cancer, 9 and thyroid papillary carcinoma, 10 promoting cell proliferation and invasion. High caveolin-1 level had been demonstrated to confer favorable prognoses in bile duct and breast carcinomas, 11 but is correlated with poor prognoses in prostate, esophageal, renal and non-small-cell lung carcinoma. 8, 12, 13 These differences appear to depend on the cellular/tissue context. Nevertheless, within the same tumor type such as gastric cancer, a contradictory behavior of caveolin-1 was also observed. It is downregulated in neoplastic mucosa samples from primary tumors but restored in distant metastases. 14 Similarly, in pancreatic cancer, caveolin-1 is reduced in the precancerous lesion, such as pancreatic intraductal papillarymucinous neoplasms, compared with normal tissue, but is highly expressed in invasive tumors compared with noninvasive tumors. 15 In addition to its epigenetic or genetic alterations and different co-effectors or signaling pathways, [16] [17] [18] [19] the 'functional fluctuation' of caveolin-1 noted in current studies is assumed to be attributed to the regulation from its protein interaction partners (that is, structural molecules). However, the detailed mechanism is unclear.
Cavins are another abundant structural protein family of caveolae. They facilitate caveolin-1 to form caveolae, and maintain the stability of the caveolae structure, 2, 20 thus providing a possible mechanistic insight into caveolin-1 functional regulation. Such caveolae accessory proteins include cavin-1 and its homologs, cavin-2, -3, and -4, with differing and specific properties. [21] [22] [23] [24] We here investigated the significance of all four cavins in caveolin-1-related aggressiveness, and consequently identified an indispensable role of cavin-1 in pancreatic cancer progression. All results support the modulation of cavin-1 on functional fluctuation of caveolin-1 in pancreatic cancer development. Interrupting the cavin-1/caveolin-1 interaction by targeting cavin-1, therefore, provides a potential alternative therapeutic approach for the treatment of pancreatic cancer.
RESULTS
Caveolin-1 expression is positively related to metastatic potential and prognosis of pancreatic cancer The expression profile of caveolin-1 in pancreatic cancer cell lines indicated that caveolin-1 level was increased in parallel with the metastatic potential of pancreatic cancer cells: the caveolin-1 mRNA and protein levels in high-metastatic SW1990HM or L3.6pl cells were significantly higher than that in the low-metastatic Capan-1, SW1990 or COLO357 cells ( Figures 1A and B) .
Tissue microarray (TMA) analyses based on two independent pancreatic cancer cohorts showed that caveolin-1 expression was positively associated with tumor lymphatic metastasis (P ¼ 0.012) and tumor node metastasis stage (P ¼ 0.031; Supplementary Table 1 ). High caveolin-1 level was an independent predictor for shorter overall survival (hazard ratio ¼ 1.924, P ¼ 0.029) and time to recurrence (hazard ratio ¼ 1.733, P ¼ 0.039) in patients (Supplementary Table 2 and Figures 1C and D) .
Cavin-1 interacts with caveolin-1 and correlates to metastatic potential of pancreatic cancer cells We previously identified cavin-1 as a caveolin-1-interacting protein using a yeast two-hybrid screen (Xu HX, et al. unpublished data). Here, co-immunoprecipitation (IP) assays revealed the physical association between cavin-1 and caveolin-1 in SW1990HM and L3.6pl cells (Figure 2a) . Their colocalization in the cytomembrane or cytoplasm in these cells was also indicated by an immunofluorescence assay (Figure 2b ). Nevertheless, caveolin-1 antibody failed to co-IP with cavin-1 in HPDE and hTERT-HPNE cells. This was possibly due to the low expression of cavin-1 in these cells, because forced expression of cavin-1 resulted in co-IP with caveolin-1, and the converse IP of cavin-1 by caveolin-1 led to a similar result (Figure 2c ). Other cavin-1 homologs, 2 including cavin-2 and cavin-3, were also found to be co-IP with caveolin-1 in SW1990HM and L3.6pl cells (Supplementary Figure 1A) . However, only cavin-1 exhibited a stepwise upregulation with increasing aggressiveness in pancreatic cancer cells, and very low or undetectable in untransformed pancreatic cells (Figure 2d ). Cavin-1 knockdown by short hairpin RNA not only reduced caveolin-1 expression, but also led to loss of cavin-2 and cavin-3 ( Figure 2e ). Cavin-2 presented similar interactions with caveolin-1 and cavin-1, whereas its expression did not correlate with metastatic potential in pancreatic cancer cells. Yet much less molecular interactions and malignant relevance were observed in cavin-3 ( Supplementary  Figures 1B and C) .
Cavin-1 enhances caveolin-1-modulated metastatic potential in pancreatic cancer cells Given these molecular links, we further explored the regulation of cavin-1 on caveolin-1 in more detailed functional studies. The role of cavin-2 was also examined because of its physical interaction with caveolin-1. Two pancreatic cancer cell lines, including Capan-1 with low level of cavin-1, -2 and caveolin-1, and L3.6pl with high levels of all three proteins, were used. Untransformed HPDE cells were also included because they lack cavin-1, -2, yet possess endogenous caveolin-1. All transfection efficiencies in these cells were shown in Supplementary Figure 2 . We found that overexpression of caveolin-1 alone only elicited a modest activation of Rho kinases and MMP-9 in Capan-1 cells, compared with controls ( Figure 3a) . It did not significantly increase in vitro invasiveness or in vivo pulmonary metastasis of these cells. Whereas further addition of cavin-1 augmented these effects (Figures 3b-d) , but cavin-2 did not (Supplementary Figure 3A-C) . Transfected HPDE cells also had similar synergistic effects in the setting of endogenous caveolin-1. As shown in Supplementary  Figures 3D and E, these cells exhibited a significant activation of Rho kinases and enhancement of migration owing to transfection of cavin-1 rather than cavin-2. In contrast, knockdown of either cavin-1 or cavin-2 markedly inhibited activations of Rho kinases and MMP-9 in L3.6pl cells, and reduced in vitro invasiveness as well as in vivo peritoneal or liver metastasis of these cells. Of note, although both L3.6pl-shcavin-1 and -shcavin-2 cells showed significant downregulation of cavin-1, -2 and caveolin-1, upon caveolin-1 restoration, further transfection of cavin-1 almost completely abrogated cavin-2 knockdown-induced effects, but transfection of cavin-2 did not reverse the suppressive phenotypes because of cavin-1 silencing (Figure 4 and Supplementary Figure 4 ). All data clearly indicate that cavin-1, but not cavin-2, cooperates with caveolin-1 to enhance pancreatic cancer cell aggressiveness. Reciprocally, knockdown of caveolin-1 in L3.6pl cells induced the molecular or functional changes similar to those in cavin-1 knockdown cells, but did not affect cavin-1 expression (Supplementary Figure 5) . Likewise, silencing caveolin-1 in HPDE cells almost completely offset cavin-1-enhanced migration (data not shown). These findings suggest that caveolin-1 is also indispensable for the tumor-promoting function of cavin-1 in pancreatic cancer cells.
Cavin-1 enhances the prognostic potency of caveolin-1 in pancreatic cancer Analyses of TMAs revealed a significant relevance between caveolin-1 and cavin-1 expression in pancreatic cancer tissues (r ¼ 0.340, P ¼ 0.004 in cohort I and r ¼ 0.327, P ¼ 0.002 in cohort II; Spearman's rank correlation test). The prognostic potency of caveolin-1 was enhanced by cavin-1: combination of both factors more reliably predicted survival (P ¼ 0.001 in cohort I and P ¼ 0.001 in cohort II) and recurrence (P ¼ 0.002 in cohort I and Po0.001 in cohort II) in pancreatic cancer patients. Subgroup analyses especially showed that high caveolin-1 levels predicted a poor prognosis only in patients with high cavin-1 expression, but not in patients with low cavin-1 level (Supplementary Figure 6) . Whereas no significant correlation between the expression of cavin-2, cavin-3 and caveolin-1 with poor survival of pancreatic cancer patients was observed (Supplementary Tables 1 and 2 ).
Cavin-1 remains caveolin-1 expression and location in cytomembrane in pancreatic cancer cells Based on these functional tests, we focused to analyze the interdependence between cavin-1 and caveolin-1 at the molecular level. As mentioned above, knockdown of cavin-1 markedly reduced caveolin-1 protein level in L3.6pl cells, whereas exogenous transfection of cavin-1 only led to a slight upregulation of caveolin-1 in Capan-1 cells (Figure 2e and Supplementary  Figure 2A) . Specifically, transcripts of caveolin-1 in these cells remained intact (data not shown). Glutathione S-transferase (GST) pull-down assays found that the interaction between cavin-1 and caveolin-1 was indirect because His-tagged cavin-1 failed to pull down GST-caveolin-1 fusion protein (Figure 5a ). Immunofluorescence staining further showed that caveolin-1 presented a notable intracellular translocation after cavin-1 knockdown, which was in contrast to its characteristic cytomembrane distribution in control cells. Of note, this phenotype remained unchanged despite caveolin-1 protein level was upregulated by ectopic transfection (Figure 5b ). When L3.6pl-shcavin-1 cells were treated with a lysosome inhibitor, ammonium chloride, caveolin-1 was restored, but little further accumulation was observed in control cells (Figure 5c ). All data suggest that the loss of caveolin-1 after cavin-1 knockdown is attributed to its cellular internalization and subsequent lysosomal degradation. Accordingly, transmission electron microscopy examined the density of caveolae in L3.6pl cell surface and found that caveolae (identified as characteristic 60-80 nm invaginations of the cell surface) were rare in shcavin-1 and shcavin-1/caveolin-1 cells compared with control cells (Figure 5d ).
Cavin-1 modulates caveolin-1-elicited epithelial-mesenchymal transition (EMT) in pancreatic cells associated with phosphoinositide 3-kinase (PI3K)/Akt signaling activation Baseline levels of N-cadherin, a mesenchymal molecule, exhibited a positive relevance with metastatic potential of pancreatic cancer cells and was associated with caveolin-1 or cavin-1 expression (Figure 6a ). Capan-1 cells co-transfected with caveolin-1 with cavin-1 exhibited a notable morphologic change from an epithelial-like phenotype to a fibroblast-like appearance (Figure 6b) . The molecular changes, including loss of E-cadherin, upregulation of N-cadherin or vimentin, intercellular translocation of b-catenin and augment of Snail or Slug expression, were also pronounced in these cells (Figures 6c and d) . Neither caveolin-1-cDNA nor cavin-1-cDNA alone elicited these changes. In contrast, silencing cavin-1 in L3.6pl cells reversed the morphologic changes from a scattered growth structure to the development of tightly packed colonies, and shifted gene expression from a mesenchymal to an epithelial repertoire (Figures 6b-d) . These alterations were associated with caveolin-1 exhaustion, but could not be reversed by caveolin-1 transfection. Yet knockdown of caveolin-1 alone, but concomitantly allowing cavin-1 to remain intact, induced similar effects. Moreover, immunofluorescence staining captured almost all changes consistent with EMT in these cells (Supplementary Figures 7A and B) , but in vivo analyses only partially confirmed them in L3.6pl xenografts. As shown in Supplementary Figure 7C , knockdown of cavin-1 and/or caveolin-1 led to a pronounced decrease in N-cadherin expression, compared with their respective controls, although E-cadherinpositive staining was rare regardless of the presence of cavin-1 and caveolin-1.
In addition, we found that Capan-1 cells co-transfected with cavin-1 and caveolin-1 exhibited a PI3K/Akt signaling activation as reflected by elevated expression of phosphorylated-Akt and its downstream effector phosphorylated-glycogen synthase kinase3b (Supplementary Figure 8A) . Their enhanced invasiveness (Supplementary Figure 8B) and the molecular changes consistent with EMT (Supplementary Figure 8C) were significantly inhibited by LY294002, a selective PI3K inhibitor. Similar changes were observed in HPDE cells (Supplementary Figures 8D and E) . These results suggest that PI3K/Akt signaling has a key role in the cavin-1/caveolin-1 axis-induced EMT.
DISCUSSION
The dual role of caveolin-1 in tumor development has been recognized, and is believed to be cell and tissue specific. 1, 25 We here confirm the oncogenic role of caveolin-1 in pancreatic cancer, as evidenced by its contribution to aggressiveness of pancreatic cancer cells as well as enhanced prognostic potency in caveolin-1 high patients. More importantly, our current data demonstrate for the first time that cavin-1, a structural protein of caveolae, 2 modulated the tumor-promoting function of caveolin-1 in pancreatic cancer, providing a possible explanation for the dynamic changes of caveolin-1 within the same tumor type. Detailed evidences were followed. First, in both pancreatic cancer cells and clinical samples, cavin-1 expression most closely mirrored caveolin-1 distribution. The elevated prognostic potency of caveolin-1 was approved to be dependent on high cavin-1 level in tumor tissues. Second, forced expression of cavin-1 increases HPDE cells migration in setting of endogenous caveolin-1, and augments Capan-1 cells invasiveness in coordination with exogenous caveolin-1 expression. In contrast, arrest of cavin-1 expression notably reduced in vitro invasion and in vivo metastasis in L3.6pl cells. Third, cavin-1 knockdown concomitantly reduced caveolin-1 protein expression and caveolae density (reflected the activated-type of caveolin-1 2,21 ) in L3.6pl cells. These phenotypes were demonstrated to be attributed to caveolin-1 cellular internalization after cavin-1 loss, and subsequent lysosomal degradation. Fourth, transfection of caveolin-1 with cavin-1, but not caveolin-1 alone, activated PI3K/Akt signaling and elicited a characteristic change consistent with EMT in Capan-1 cells. In contrast, reduction of cavin-1 in L3.6pl cells induced an arrest of PI3K/Akt signaling and completely or partially reversed EMT markers to the epithelial state. Finally, shcaveolin-1 cells exhibited suppressive phenotypes similar to cavin-1 knockdown and shcavin-1 cells had a simultaneous loss of caveolin-1, however, restoring caveolin-1 alone in shcavin-1 cells failed to abrogate cavin-1-silencing-induced effects.
The functional fluctuation of caveolin-1 within the same tumor type is different from the variance in termed of cell/tissue specificity. 1, 25 It is reflected by a biphasic expression pattern of caveolin-1 as reported previously. 15 We indeed observed an abnormal expression of caveolin-1 in untransformed pancreatic cells and adjacent non-neoplastic tissues, which were even higher that in low-malignant pancreatic cancer cells or tissues (data not shown). Most analyses suggested that it might involve the activation status of different domains in caveolin-1 as well as various co-effectors and downstream signals in between cancerous and non-cancerous samples. [17] [18] [19] For example, Erk signaling is activated by caveolin-1 and subsequently promotes tumor growth and survival, whereas p38 mitogen-activated protein kinase activation predicts loss of caveolin-1, inducing cell migration/invasion. 17, 25 Based on the above evidences, we propose that deprivation of pro-malignant function of caveolin-1 in these non-neoplastic cells/tissues is due to the absence of cavin-1, at least partially. As shown, (1) upregulation of caveolin-1 did not significantly increase aggressiveness of pancreatic cancer cells with low cavin-1 level; (2) restoring cavelin-1 alone failed to abrogate cavin-1-silencing-induced effects; (3) the prognostic value of caveolin-1 in pancreatic cancer tissues was only achieved in cavin-1 high tumors. Specifically, this notion is based on the relationship between cavin-1 and caveolin-1 with caveolae structure, [21] [22] [23] [24] identification of the role of cavin-1 therefore adds to the existing data for modulating caveolin-1 dynamics in caveolae structural adjustment.
Similar to caveolin-1, the role of cavin-1 on tumor development remains elusive. Previous studies have proved its suppressor role in tumor that cavin-1 expression negatively correlated to prostate, breast and non-small-cell lung cancer progression. 26, 27 We here Cavin-1 potentiates caveolin-1 pro-tumor function L Liu et al support the oncogenic role of cavin-1 in pancreatic cancer, in contrast to previous reports. Detailed evidences were shown above. Furthermore, we found, (1) upregulation of cavin-1 alone failed to increase the invasiveness of Capan-1 cells in the absence of caveolin-1, but the combination of caveolin-1 with cavin-1 elicited a pronounced pro-metastatic effect; (2) depletion of caveolin-1 inhibited cavin-1-mediated invasiveness in L3.6pl cells without affecting cavin-1 expression; (3) cavin-1 was not identified as a risk factor for the poor survival in pancreatic cancer patients, and achieved a significant prognostic value only in caveolin-1 high tumor (Supplementary Figure 6) . These findings suggest that the pro-tumor function of cavin-1 is reversely dependent on caveolin-1. It highlights the interdependence between cavin-1 and caveolin-1 in contributing to pancreatic cancer progression. In addition, the role of caveolae in these interactions between cavin-1 and caveolin-1 needs attention because caveolae is a main functional platform of cavin-1 or caveolin-1 and partially reflects the activated-type caveolin-1.
2, 21 We observed a reduction of caveolae density after silencing cavin-1 and/or caveolin-1, however, it yet do not suggest that all tumor-promoting activities of cavin-1 or caveolin-1 are relied on the presence of caveolae. For example, leukocytes lack caveolae, caveolin-1 is intimately involved in inflammatory responses and T-cell activation through modulation of cell surface molecules and cell-cell interactions. 28, 29 The prostate cancer cell line PC3 express abundant caveolin-1 but do not form caveolae; however, the endogenous caveolin-1 regulates focal adhesion turnover and cell migration. 21, 30 The significance of caveolin-1-related aggressiveness in terms of caveolae biogenesis may be not comprehensive. On the other hand, cavin-1 was initially identified as a transcription release/ terminating factor regulating the expression of multiple genes, such as the type I collagen transcription factor BFCOLI. 31, 32 Its contribution to caveolin-1 function therefore may be greater than a simple reflection of caveolae formation. Subsequent experiments on this notion deserved to explore.
Taken together, this study elucidates the oncogenic function of caveolin-1 in pancreatic cancer progression, and indicates its functional fluctuates with stage alterations. More importantly, it highlights the indispensible role of cavin-1, a caveolae-accessory protein, in caveolin-1-related aggressiveness, suggesting a mechanism that is partially dependent on caveolae structure, and underlying caveolin-1 fluctuations in pancreatic cancer development. Our data identified a previously uncharacterized role of the cavin-1/caveolin-1 axis as a prognostic biomarker in pancreatic cancer, providing a potential therapeutic target for future treatment of the disease.
MATERIALS AND METHODS

Cell lines
Five human pancreatic cancer cell lines with various metastatic potentials were used in this study. Capan-1, SW1990 and COLO357 cells were obtained from the American Type Culture Collection (Manassas, VA, USA) and grown in complete growth media. SW1990HM 33 and L3.6pl 34 cells were derived from parent cell lines (SW1990 and COLO357, respectively) that had undergone metastasis from the pancreas to the liver in nude mice. Two human pancreatic duct epithelial cell lines, HPDE and hTERT-HPNE, were obtained from the Japanese Cancer Research Resources Bank (Tokyo, Japan).
Cell transfection and clone selection
Human cavin-1, cavin-2 and caveolin-1 cDNAs were amplified using standard reverse transcription-PCR (RT-PCR) from RNA extracted from Capan-1 cells using the following primers: 22 0 was used to generate the negative control plasmid pLKO.1-Src.
All plasmids were transfected into target cells using lentiviral vectors (Invitrogen) as described previously. 36 Drug selection of the cells was performed using G418 (200 mg/ml for HPDE, 500 mg/ml for Capan-1) or puromycin (4 mg/ml for L3.6pl) for 5-7 days. Stably transfected clones were characterized using immunoblots to detect the protein levels of cavin-1 and caveolin-1. Clones with relatively high expression of the transfected genes were selected for further analyses.
Drug treatment
Cells were treated with the lysosome inhibitor ammonium chloride (Sangon, Shanghai, China) at a final concentration of 20 mM for 6 h before analyzing caveolin-1 levels in cell lysates. 21 They were also treated with the PI3K inhibitor LY294002 (40 mM; Sigma-Aldrich, St Louis, MO, USA) for 72 h to examine the expression of Akt, phosphorylated-Akt, glycogen synthase kinase-3b and phosphorylated-glycogen synthase kinase-3b. 37 RT-PCR, quantitative RT-PCR, immunoblotting, immunofluorescence, gelatin zymography, co-IP and GST pull-down assays Immunofluorescence, immunoblotting, gelatin zymography and co-IP assays were performed according to as described previously. 36 Information regarding RT-PCR, quantitative RT-PCR and GST pull-down assays is in the Supplementary Materials and methods.
Cell migration and invasion assays
Cell motility was assessed by measuring the movement of cells into a scrape created with a 10-ml pipette tube. The speed of wound closure was monitored after 48 h.
Invasion assays were performed in 24-well BioCoat Matrigel Invasion Chambers (Corning Costar Corp., Cambridge, UK) using 5 Â 10 5 cells in serum-free Dulbecco's modified Eagle's medium and plated onto Matrigelcoated filters. Conditioned media supplemented with 20% fetal calf serum and NIH/3T3-conditioned media (1:1) was placed in the lower chambers as a chemoattractant. After 72 h, cells that migrated to the underside of the membrane were stained with Giemsa (Sigma, Rowville, VIC, Australia) and counted at Â 200 magnification under a microscope (Olympus, Tokyo, Japan).
In vivo metastasis assays
Forty-eight male BALB/c nu/nu mice, 4-6 weeks old and weighing approximately 20 g, were obtained from the Shanghai Institute of Materia Medica, Chinese Academy of Science, and maintained under specific pathogen-free conditions. The experimental protocol was approved by the Shanghai Medical Experimental Animal Care Commission.
A total of 1.0 Â 10 6 Capan-1-RFP-Mock, Capan-1-RFP-cavin-1, Capan-1-RFP-caveolin-1, Capan-1-RFP-cavin-1/caveolin-1, Capan-1-RFP-cavin-2 or Capan-1-RFP-cavin-2/caveolin-1 cells were injected into the lateral tail vein of 48 nude mice to establish the 'experimental metastatic' model. Eight mice were in each group. Mice were killed after 8 weeks and subjected to fluorescence stereomicroscopy (Leica Microsystems Imaging Solutions, Ltd, Cambridge, UK) to detect the occurrence of metastasis as described. 36 Metastasis was analyzed quantitatively by integrated optical density measurements and histopathologically according to previous methods. 36 To establish the 'spontaneous metastatic' model, 1.0 Â 10 6 L3.6pl-RFP-Mock, L3.6pl-RFP-shcavin-1, L3.6pl-RFP-shcavin-1/caveolin-1-cDNA, L3.6pl-RFP-shcavin-1/caveolin-1-cDNA þ cavin-2-cDNA, L3.6pl-RFPshcavin-2, L3.6pl-RFP-shcavin-2/caveolin-1-cDNA, L3.6pl-RFP-shcavin-2/ Cavin-1 potentiates caveolin-1 pro-tumor function L Liu et al caveolin-1-cDNA þ cavin-1-cDNA or L3.6pl-RFP-shcaveolin-1 cells were injected subcapsularly into the pancreas of 64 nude mice under anesthesia with ketamine/xylazine after opening up the abdomen, respectively. Mice were monitored once every 3 days for 35 days before kill. Their visceral organs, including the lungs, liver and lymph nodes, were examined as described above for occurrence of metastases. Eight mice were in each group.
